Nordea Bank Abp

  • ISIN: CH0284415681
  • Land: Schweden

Nachricht vom 26.11.2021 | 08:00

Nordea Bank Abp: Transaction in Own Shares

EQS Group-News: Nordea Bank Abp / Key word(s): Miscellaneous
26.11.2021 / 08:00

Nordea Bank Abp: Repurchase of own shares on 25.11.2021

Nordea Bank Abp
Stock exchange release - Changes in company's own shares
25.11.2021 at 22.30 EET

Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 25.11.2021 completed repurchases of own shares (ISIN: FI4000297767) as follows:

Trading venue (MIC Code) Number of shares Weighted average price / share, EUR* ** Total cost, EUR* **
XSTO 611,410 10.88 6,650,398.29
XHEL 417,737 10.86 4,535,621.25
CEUX 356,511 10.87 3,875,168.39
AQEU 47,083 10.88 512,086.89
TQEX 7,416 10.87 80,610.61
XCSE 48,976 10.86 531,767.75
Total 1,489,133 10.87 16,185,653.18
 

* FX rate used: SEK to EUR 10.1685 and DKK to EUR 7.4361
** Rounded to two decimals

On 20 October 2021, Nordea announced a share buy-back programme of up to a maximum of EUR 2.0bn based on the authorisation granted by Nordea's Annual General Meeting on 24 March 2021. The repurchase of own shares in public trading is executed in accordance with Regulation No. 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052.

After the disclosed transactions, Nordea holds 26,399,644 treasury shares for capital optimisation purposes and 7,112,244 treasury shares for remuneration purposes.

Details of each transaction are included as an appendix to this announcement.
http://www.rns-pdf.londonstockexchange.com/rns/7120T_1-2021-11-26.pdf

On behalf of Nordea Bank Abp,

Morgan Stanley Europe SE

For further information:

Matti Ahokas, Head of Investor Relations, +358 9 5300 8011
Group Communication, +358 10 416 8023 or press@nordea.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.



End of Media Release



show this

GBC im Fokus

IGEA Pharma N.V. Realignment to CBD extraction

The goal is to become the quality and cost leader in the field of CBD in Europe. To this end, a GMP pharma compliant plant is being built in Switzerland. The supercritical CO2 extraction process is to be used to achieve the highest standard of quality. The CBD market is growing strongly and with the focus on quality leadership and pure extraction, IGEA Pharma's new business model should be able to occupy an attractive niche market. With the proprietary supercritical CO2-extraction technology, other markets such as vanilla, rose or rosemary can be developed in the medium term. Based on our DCF model, we have determined a fair value of € 1.05 (CHF 1.13) per share and assign a BUY rating.

News im Fokus

Allianz SE: Allianz kündigt Abschluss eines Rückversicherungsvertrages in den USA an

03. Dezember 2021, 07:03

Aktueller Webcast

Deutsche Konsum REIT-AG

FY 2020/2021 Financial Results

16. Dezember 2021

Aktuelle Research-Studie

CEWE Stiftung & Co. KGaA

Original-Research: CEWE Stiftung & Co. KGaA (von GSC Research GmbH): Kaufen

02. Dezember 2021